Selected research
Industry Research
Dasatinib Generics Industry Research Report 2026
Market perspective
The global Dasatinib Generics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dasatinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dasatinib Generics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dasatinib Generics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dasatinib Generics include Bristol Myers Squibb, Lupin, Sawai Pharmaceutical, XSpray Pharma, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical and Chia Tai Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dasatinib Generics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dasatinib Generics Market by Company
Bristol Myers Squibb
Lupin
Sawai Pharmaceutical
XSpray Pharma
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Dasatinib Generics Segment by Type
80mg per Tablet
70mg per Tablet
50mg per Tablet
20mg per Tablet
140mg per Tablet
100mg per Tablet
Dasatinib Generics Segment by Application
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Dasatinib Generics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dasatinib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dasatinib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dasatinib Generics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dasatinib Generics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dasatinib Generics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dasatinib Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 80mg per Tablet
- 70mg per Tablet
- 50mg per Tablet
- 20mg per Tablet
- 140mg per Tablet
- 100mg per Tablet
Applications
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
Companies covered
- Bristol Myers Squibb
- Lupin
- Sawai Pharmaceutical
- XSpray Pharma
- Qilu Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dasatinib Generics Market Size (2021-2032)
- 2.2.2 Global Dasatinib Generics Sales (2021-2032)
- 2.2.3 Global Dasatinib Generics Market Average Price (2021-2032)
- 2.3 Dasatinib Generics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 80mg per Tablet
- 2.3.3 70mg per Tablet
- 2.3.4 50mg per Tablet
- 2.3.5 20mg per Tablet
- 2.3.6 140mg per Tablet
- 2.3.7 100mg per Tablet
- 2.4 Dasatinib Generics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Acute Lymphocytic Leukemia
- 2.4.3 Chronic Myeloid Leukemia
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dasatinib Generics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dasatinib Generics Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Dasatinib Generics Revenue of Manufacturers (2021-2026)
- 3.4 Global Dasatinib Generics Average Price by Manufacturers (2021-2026)
- 3.5 Global Dasatinib Generics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dasatinib Generics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dasatinib Generics, Product Type & Application
- 3.8 Global Manufacturers of Dasatinib Generics, Established Date
- 3.9 Global Dasatinib Generics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol Myers Squibb
- 4.1.1 Bristol Myers Squibb Company Information
- 4.1.2 Bristol Myers Squibb Business Overview
- 4.1.3 Bristol Myers Squibb Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol Myers Squibb Dasatinib Generics Product Portfolio
- 4.1.5 Bristol Myers Squibb Recent Developments
- 4.2 Lupin
- 4.2.1 Lupin Company Information
- 4.2.2 Lupin Business Overview
- 4.2.3 Lupin Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lupin Dasatinib Generics Product Portfolio
- 4.2.5 Lupin Recent Developments
- 4.3 Sawai Pharmaceutical
- 4.3.1 Sawai Pharmaceutical Company Information
- 4.3.2 Sawai Pharmaceutical Business Overview
- 4.3.3 Sawai Pharmaceutical Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sawai Pharmaceutical Dasatinib Generics Product Portfolio
- 4.3.5 Sawai Pharmaceutical Recent Developments
- 4.4 XSpray Pharma
- 4.4.1 XSpray Pharma Company Information
- 4.4.2 XSpray Pharma Business Overview
- 4.4.3 XSpray Pharma Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 XSpray Pharma Dasatinib Generics Product Portfolio
- 4.4.5 XSpray Pharma Recent Developments
- 4.5 Qilu Pharmaceutical
- 4.5.1 Qilu Pharmaceutical Company Information
- 4.5.2 Qilu Pharmaceutical Business Overview
- 4.5.3 Qilu Pharmaceutical Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Qilu Pharmaceutical Dasatinib Generics Product Portfolio
- 4.5.5 Qilu Pharmaceutical Recent Developments
- 4.6 CSPC Ouyi Pharmaceutical
- 4.6.1 CSPC Ouyi Pharmaceutical Company Information
- 4.6.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.6.3 CSPC Ouyi Pharmaceutical Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 CSPC Ouyi Pharmaceutical Dasatinib Generics Product Portfolio
- 4.6.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.7 Chia Tai Tianqing Pharmaceutical
- 4.7.1 Chia Tai Tianqing Pharmaceutical Company Information
- 4.7.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 4.7.3 Chia Tai Tianqing Pharmaceutical Dasatinib Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Chia Tai Tianqing Pharmaceutical Dasatinib Generics Product Portfolio
- 4.7.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Dasatinib Generics Market Scenario by Region
- 5.1 Global Dasatinib Generics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dasatinib Generics Sales by Region: 2021-2032
- 5.2.1 Global Dasatinib Generics Sales by Region: 2021-2026
- 5.2.2 Global Dasatinib Generics Sales by Region: 2027-2032
- 5.3 Global Dasatinib Generics Revenue by Region: 2021-2032
- 5.3.1 Global Dasatinib Generics Revenue by Region: 2021-2026
- 5.3.2 Global Dasatinib Generics Revenue by Region: 2027-2032
- 5.4 North America Dasatinib Generics Market Facts & Figures by Country
- 5.4.1 North America Dasatinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dasatinib Generics Sales by Country (2021-2032)
- 5.4.3 North America Dasatinib Generics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dasatinib Generics Market Facts & Figures by Country
- 5.5.1 Europe Dasatinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dasatinib Generics Sales by Country (2021-2032)
- 5.5.3 Europe Dasatinib Generics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dasatinib Generics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dasatinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dasatinib Generics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dasatinib Generics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dasatinib Generics Market Facts & Figures by Country
- 5.7.1 South America Dasatinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dasatinib Generics Sales by Country (2021-2032)
- 5.7.3 South America Dasatinib Generics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dasatinib Generics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dasatinib Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dasatinib Generics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dasatinib Generics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dasatinib Generics Sales by Type (2021-2032)
- 6.1.1 Global Dasatinib Generics Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Dasatinib Generics Sales Market Share by Type (2021-2032)
- 6.2 Global Dasatinib Generics Revenue by Type (2021-2032)
- 6.2.1 Global Dasatinib Generics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dasatinib Generics Revenue Market Share by Type (2021-2032)
- 6.3 Global Dasatinib Generics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dasatinib Generics Sales by Application (2021-2032)
- 7.1.1 Global Dasatinib Generics Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Dasatinib Generics Sales Market Share by Application (2021-2032)
- 7.2 Global Dasatinib Generics Revenue by Application (2021-2032)
- 7.2.1 Global Dasatinib Generics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dasatinib Generics Revenue Market Share by Application (2021-2032)
- 7.3 Global Dasatinib Generics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dasatinib Generics Value Chain Analysis
- 8.1.1 Dasatinib Generics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dasatinib Generics Production Mode & Process
- 8.2 Dasatinib Generics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dasatinib Generics Distributors
- 8.2.3 Dasatinib Generics Customers
9 Global Dasatinib Generics Analyzing Market Dynamics
- 9.1 Dasatinib Generics Industry Trends
- 9.2 Dasatinib Generics Industry Drivers
- 9.3 Dasatinib Generics Industry Opportunities and Challenges
- 9.4 Dasatinib Generics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst